Navigation Links
IDM Pharma Announces Updated Phase 3 Mifamurtide (L-MTP-PE) Data Confirms Statistically Superior Overall Survival in Osteosarcoma Patients
Date:11/1/2007

MEA application is currently under review and the Company continues to work closely with the regulatory body to ensure it has the information needed to approve L-MTP-PE.

About Osteosarcoma

About 3 percent of all childhood cancers are osteosarcoma. Because osteosarcoma usually develops from osteoblasts, it most commonly affects children and young adults experiencing their adolescent growth spurt. Boys and girls have a similar incidence rate until later in their adolescence, when boys are more commonly affected. While most tumors occur in larger bones, such as the femur, tibia, and humerus, and in the area of the bone that has the fastest growth rate, they can occur in any bone. The most common symptom is pain, but swelling and limited movement can occur as the tumor grows.

Osteosarcoma is an orphan disease with fewer than 1,000 new cases diagnosed in the U.S. each year. A similar incidence of the disease exists in Europe. According to the Children's Oncology Group, the survival of children with osteosarcoma has remained at 60-65 percent since the mid-1980s. The standard treatment for osteosarcoma is tumor resection with combination chemotherapy before and after surgery.

About IDM Pharma

IDM Pharma is focused on the development of innovative cancer products that either destroy cancer cells by activating the immune system or prevent tumor recurrence by triggering a specific adaptive immune response. IDM Pharma is dedicated to maximizing the full therapeutic and commercial potential of each of its innovative products to address the needs of patients and the physicians who treat these patients.

For more information about the company and its products, visit http://www.idm-pharma.com.

Forward-Looking Statements

This press release includes and the presentation described in this press release will include forward-looking statements that reflect management's current views of
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 2, 2015   Emerson Ecologics, LLC ... supplements, prescription products and natural health and ... with Anabolic Laboratories, a leading manufacturer of ... new partnership will allow Anabolic Laboratories to ... practitioner segments and provide customers with added ...
(Date:3/2/2015)... Calif. , March 2, 2015 Nevro ... company that has developed and commercialized an innovative, evidence-based ... announced that Brad Vale , PhD, DVM, former ... been appointed to its Board of Directors, effective March ... 30 years of experience in developing, commercializing and investing ...
(Date:3/2/2015)... 2015  BC Technical, the nation,s leading non-OEM ... Systems, a Nuclear Imaging service company providing systems, ... their ongoing vision to provide the best, and ... Technical continues to expand their reach and expertise. ... valuable resources and knowledge in addition to strengthening ...
Breaking Medicine Technology:Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 2Anabolic Laboratories Selects Emerson Ecologics As Distribution Partner 3Nevro Appoints Dr. Brad Vale to its Board of Directors 2BC Technical Acquires Eclipse Systems 2
... 10 Biopure Corporation,(Nasdaq: BPUR ) today announced ... have been published in the June 2008 issue of,the ... an Alternative,to Blood Transfusion: Efficacy and Safety Evaluation in ... "It is gratifying to have experts cull through the ...
... Endpoints for Advair Diskus(R) ... Compared to ... African American,patients with asthma treated with Advair Diskus, a combination ... propionate, had a lower rate of exacerbations when,compared with patients ...
Cached Medicine Technology:Biopure Phase III Orthopedic Trial Results Published in Journal of Trauma 2Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma 2Results From One-Year Study Suggest Advair(R) Provides Important Benefits for African American Patients With Asthma 3
(Date:3/2/2015)... Today the Brain Injury Association of America (BIAA) officially kicked ... support the more than 5.3 million Americans who are living ... nation in observing Brain Injury Awareness Month by conducting an ... the 2015 to 2017 campaign is: Not Alone. , ... general public about the incidence of brain injury and the ...
(Date:3/2/2015)... Market Publishers Ltd is extremely happy ... Global Industry Analysts Inc and recently added to its ... . Through 2018, the global radiation therapy equipment market ... research report suggests a holistic analysis of the situation ... well as covers the top market trends. The publication ...
(Date:3/2/2015)... 02, 2015 Tyrone Christopher, Co-founder of ... medium for the model agency industry, have launched Softcandy.sexy, ... Mango, Passion Fruit, Pink Grapefruit, Pomegranate, and or Vanilla ... 1pm. , At a cost of alienating a few ... fire by announcing the brands commitment and support of ...
(Date:3/2/2015)... 02, 2015 After a rigorous evaluation ... service, pricing and long-term strategy, Blood Centers of America ... choice for member centers’ testing needs. , BCA, which ... more than 30 percent of the U.S. blood supply, ... “BCA is committed to drive cost savings to members,” ...
(Date:3/2/2015)... View, CA (PRWEB) March 02, 2015 ... today that it has officially launched a multivitamin ... Gustafsson, head of product development for BNatrl, said ... through feedback from Olympic and other world-class athletes. ... excited to use this pure whole food multivitamin ...
Breaking Medicine News(10 mins):Health News:Brain Injury Association of America Launches “Not Alone” Campaign for Brain Injury Awareness Month 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 2Health News:New Topical Research Reports Prepared by GIA Now Available at MarketPublishers.com 3Health News:Sex Sells! A Newly Minted Organic Bodycare Brand Courts Controversy at a Cost 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 2Health News:Blood Centers of America Chooses QualTex Laboratories as Vendor of Choice 3Health News:Bnatrl Launches Multivitamin Supplement for Runners 2
... ... a permanent solution to the Medicare physician payment system this year, says MedicareSupplementPlans.com ... Los ... year designed to improve the way Medicare pays physicians while still keeping Medicare costs ...
... , Senate Finance Committee Urged Not to Include ... WASHINGTON, Aug. 7 America,s local and regional independent ... provision imposing a 20% co-pay on laboratory services under Medicare. ... this provision would shift billions of dollars in costs to senior ...
... Duane Reade Holdings, Inc. announced today that its wholly-owned ... had closed their offering of $300.0 million aggregate principal amount ... The Notes bear interest at an annual rate of ... yield to maturity of 12.375%. The Notes were issued ...
... serious cardiovascular issues: study , FRIDAY, Aug. 7 (HealthDay ... is a reliable predictor of cardiovascular complications in people ... -- kidney damage caused by diabetes. , The study ... 2007. Those with increased levels of IgM in their ...
... , , , ... will learn how to use the latest technology to help keep ... California Partnership to End Domestic Violence (CPEDV) and Verizon. , ... the Verizon Foundation, the philanthropic arm of Verizon, is designed to ...
... the Yerkes National Primate Research Center, Emory University, believe ... explored in the development of an effective AIDS vaccine. ... nonhuman primates, they propose an additional new approach to ... in the August issue of Nature Medicine . ...
Cached Medicine News:Health News:Congress Unlikely to Pass Permanent Medicare Physician Payment Fix in 2009, says MedicareSupplementPlans.com 2Health News:Seniors: Get Your Checkbooks Ready 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 2Health News:Duane Reade Holdings, Inc. Announces Closing of Offering of $300 Million of 11.75% Senior Secured Notes Due 2015 3Health News:Immunoglobulin Can Predict Some Diabetic Complications 2Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 2Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 3Health News:Verizon and California Partnership to End Domestic Violence Launch Program to Help Victims Protect Themselves by Using Technology 4Health News:Yerkes researchers propose ambitious new strategies for AIDS vaccine research 2Health News:Yerkes researchers propose ambitious new strategies for AIDS vaccine research 3
Excellent during IOL insertion while pushing the trailing haptic into position. Gently curved shaft and round handle....
Ideal for nucleus manipulation during phacoemulsification. Also used for manipulating and rotating IOLs within the anterior chamber. Round knurled handle...
Short, narrow paddle angled 45 degree inserts through the side port stab incision and is ideal for effective manipulation of the lens during anterior chamber phacoemulsification....
Nucleus divider with 1.25 mm tip and blade offset at a 60 degree angle is ideal for performing the "Phaco Chop" technique. Round knurled handle. Manufactured in titanium....
Medicine Products: